
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
PHMR | Madrid | EUR | Delayed | |
PHMR | Derived | EUR | Real-time | |
PHMMF | OTC Markets | USD | Delayed | |
0RC6 | London | EUR | Real-time | |
PMRA | Frankfurt | EUR | Delayed | |
PHMA | Vienna | EUR | Real-time |
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca is a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma. The company develops Ecubectedin (PM14), which is in phase I/II clinical trials with ecubectedin attained the optimal dose for the treatment of advanced solid tumors, as well as in Phase Ib trial with ecubectedin in combination with atezolizumab for the treatment of advanced solid tumors; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating choroidal neovascularization, such as macular degeneration and diabetic retinopathy; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Name | Age | Since | Title |
---|---|---|---|
Jose Maria Fernandez Sousa-Faro | - | 1986 | Founder, Executive Chairman, CEO & President |
Montserrat Andrade Detrell | - | - | Proprietary Director |
Eduardo Serra Rexach | 76 | 2021 | Independent Other External Director |
M. Carlos Solchaga Catalan | 78 | - | Independent Other External Director |
Blanca Hernandez Rodriguez | - | 2019 | Independent Director |
Maria Sandra Ortega Mera | - | 2020 | Representative Proprietary Director |
Emiliano Calvo Aller | - | 2022 | Independent Director |
Mariano Esteban Rodriguez | - | 2022 | Independent Coordinating Director |
Fernando Martin-Delgado Santos | - | - | Independent Other External Director |
Rosa Maria Sanchez-Yebra Alonso | - | 2022 | Independent Director |
Soledad Cuenca Miranda | - | 2023 | Independent Director |
Pedro Francisco Fernandez Puentes | - | - | Executive Vice-Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review